FindTrial
Sign In

Early clozapine discontinuation: who is at risk?

Early clozapine discontinuation: who is at risk? Development of a multivariate prediction model for clozapine discontinuation in a patient population with psychotic disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON20555
Enrollment
Unknown
Registered
2015-09-10
Start date
2015-10-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychotic disorders, Schizophrenia, Schizoaffective disorders Psychotische stoornissen,Schizofrenie, Schizoaffectieve stoornissen

Interventions

not applicable (predictive modelling study)

Sponsors

Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients, aged 18 years or older, of whom demographical, medical and social data are registered in the AHD and the PCR-MN, between 2001 and 2014, who have been prescribed clozapine are eligible for the study.

Exclusion criteria

Exclusion criteria: -the absence of any drug-dispensing records over the past two years before introduction of clozapine. -the absence of drug-dispensing data of any drug in the 12 weeks after cessation of clozapine, if applicable,

Design outcomes

Primary

MeasureTime frame
Discontinuation of clozapine use within one year after the start is the main outcome measure.—

Secondary

MeasureTime frame
Discontinuation of clozapine use within 6 months after the start is the main outcome measure.—

Contacts

Public ContactMarieke Beex-Oosterhuis
mariekeoosterhuis@hotmail.com0031-78-6523103

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)